BRISBANE, Calif., Dec. 6, 2024 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing best-in-class products¹ targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors has granted a non-qualified employee stock options to purchase a total of 9,450 shares of common stock under the Company’s 2023 Incentive Plan.

Stock options will vest over a four-year period, with 25% of each option vesting on the first anniversary of that employee’s start date, and 1/48th of the total shares vesting. monthly thereafter, subject to continued employment at each acquisition. date.

About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company with a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a broad range of tumors. The company’s new programs range from preliminary research to later-stage investigation in a global, randomized study of first-line cancer patients. Tempest is headquartered in Brisbane, California. Further information about Tempest is available on the company’s website at www.tempesttx.com.

Investor and media contacts:

Sylvia Wheeler
Life Sciences Advisors in the Wheelhouse
[email protected]

Aljanae Reynolds
Life Sciences Advisors in the Wheelhouse
[email protected]

¹ If approved by the FDA